Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2013 Mar 1.

Published in final edited form as: Neuropharmacology. 2011 Dec 17;62(4):1874–1881. doi: 10.1016/j.neuropharm.2011.12.013

In vivo efficacies of PLP-BPI and PLP in suppressing EAE in the mouse model upon vaccination with peptides and immunization with PLP/CFA on day 0. PBS-treated mice received subcutaneous injections of 100 µl PBS on days −11, −8, and −5. PLP-BPI- and PLP-treated mice received 100 nmol/100 µl PBS on days −11, −8, and −5. The efficacy of the peptide was determined by (A) clinical disease score of EAE and (B) percent change in body weight. Results are expressed as the mean ± SEM (n = 12). EAE scores from all PLP-BPI treated mice were significantly lower than those of PBS- and PLP-treated mice (p < 0.0001). Loss of body weight was also significantly lower in PLP-BPI-treated mice compared to those treated with PBS (p < 0.0001) and PLP (p < 0.001). For statistical analysis, data points from days 10 to 25 were used.

In vivo efficacies of PLP-BPI and PLP in suppressing EAE in the mouse model upon vaccination with peptides and immunization with PLP/CFA on day 0. PBS-treated mice received subcutaneous injections of 100 µl PBS on days −11, −8, and −5. PLP-BPI- and PLP-treated mice received 100 nmol/100 µl PBS on days −11, −8, and −5. The efficacy of the peptide was determined by (A) clinical disease score of EAE and (B) percent change in body weight. Results are expressed as the mean ± SEM (n = 12). EAE scores from all PLP-BPI treated mice were significantly lower than those of PBS- and PLP-treated mice (p < 0.0001). Loss of body weight was also significantly lower in PLP-BPI-treated mice compared to those treated with PBS (p < 0.0001) and PLP (p < 0.001). For statistical analysis, data points from days 10 to 25 were used.